Research Alliance Corp III

Overview

Compare with another stock.

• TickerRACC on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersNew York, New York¹
• Incorporated inCayman Islands²
• Business address600 Fifth Avenue, 23Rd Floor, New York, Ny 10020²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Corporate structure

Research Alliance Corp III sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Research Alliance Corp III, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMatthew Hammond May 19, 2026 to now³
• Chief financial officerFrancis Sherman Adams May 19, 2026 to now⁴
• Chief operating officerHenry William Stusnick May 19, 2026 to now⁵

Timeline

1. Jul 27, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure⁷
2. May 28, 20268-K Other events⁸
3. May 21, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change⁹
4. May 19, 2026New chief executive Matthew Hammond becomes CEO³

Filings

41 filings to the SEC since October 2021: 2 quarterly reports, 3 major events, 8 insider forms, 13 large holders, 15 other. The latest 20:

1. Oct 7, 2026SCHEDULE 13G EDGAR
2. Sep 28, 2026S-4/A EDGAR
3. Sep 16, 2026425 EDGAR
4. Sep 11, 2026425 EDGAR
5. Sep 11, 2026SCHEDULE 13G EDGAR
6. Aug 24, 2026S-4 EDGAR
7. Aug 14, 2026SCHEDULE 13G EDGAR
8. Aug 14, 2026SCHEDULE 13G EDGAR
9. Aug 14, 2026SCHEDULE 13G EDGAR
10. Aug 13, 2026SCHEDULE 13G EDGAR
11. Aug 12, 202610-Q EDGAR
12. Aug 5, 2026425 EDGAR
13. Aug 3, 2026SCHEDULE 13G EDGAR
14. Jul 29, 2026425 EDGAR
15. Jul 28, 2026SCHEDULE 13D/A EDGAR
16. Jul 28, 2026425 EDGAR
17. Jul 27, 2026425 EDGAR
18. Jul 27, 20268-K EDGAR
19. Jul 2, 202610-Q EDGAR
20. May 29, 2026SCHEDULE 13D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Nantahala Capital Management, LLCSCHEDULE 13G, 1 filing Oct 7, 2026¹⁰
• GREAT POINT PARTNERS LLCSCHEDULE 13G, 1 filing Sep 11, 2026¹¹
• ADAR1 Capital Management, LLCSCHEDULE 13G, 1 filing Aug 14, 2026¹²
• BALYASNY ASSET MANAGEMENT L.P.SCHEDULE 13G, 1 filing Aug 14, 2026¹³
• TCG Crossover GP III, LLCSCHEDULE 13G, 1 filing Aug 14, 2026¹⁴
• Spruce Street Capital LPSCHEDULE 13G, 1 filing Aug 13, 2026¹⁵
• Bank of AmericaSCHEDULE 13G, 1 filing Aug 3, 2026¹⁶
• Research Alliance Holdings III LLC /CaymanSCHEDULE 13D/A, 2 filings May 29, 2026 to Jul 28, 2026¹⁷
• BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G, 1 filing May 29, 2026¹⁸
• Trails Edge Capital Partners, LPSCHEDULE 13G, 1 filing May 29, 2026¹⁹
• Commodore Capital LPSCHEDULE 13G, 1 filing May 28, 2026²⁰
• PERCEPTIVE ADVISORS LLCSCHEDULE 13G, 1 filing May 28, 2026²¹

SEC filer profile

How Research Alliance Corp III is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARResearch Alliance Corp III¹
• CIK0002118032
• Employer ID (EIN)98-1918931¹
• Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
• Incorporated inCayman Islands¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address600 Fifth Avenue, 23Rd Floor, New York, NY 10020¹
• Phone(617) 778-2500¹
• On EDGAR sinceMar 24, 2026¹
• Filings41 in all: SCHEDULE 13G (11), 3 (6), 425 (6), 8-K (3), 10-Q (2), 4 (2), S-1/A (2), 424B4 (1)¹
  All 16 form types

  8-A12B (1), CERT (1), EFFECT (1), S-1 (1), S-4 (1), S-4/A (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

• Latest filingsQuarterly report (10-Q) Aug 12, 2026
  Latest 8-K (8-K) Jul 27, 2026